Lactic Acid Bacteria Reduce MRSA Transfer

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current methods are inadequate in preventing the transfer of antibiotic-resistant pathogens like MRSA between surfaces and subjects, leading to widespread infections and a significant financial burden on healthcare systems.

Innovation Solution

A composition comprising lactic acid bacteria is used to reduce the transfer of pathogenic microorganisms between surfaces, specifically including strains like Lactobacillus and Enterococcus, which are applied topically or as oral supplements to inhibit the colonization and transfer of MRSA.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If traditional cleaning and disinfection methods are used to prevent MRSA transfer, then infection control is maintained, but the methods are inadequate and do not effectively reduce pathogen transfer

Engineering Contradiction:
Improveinfection control effectivenessVSAvoidpathogen transfer reduction
Core Design Contradiction:
ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent introduces lactic acid bacteria as an intermediary substance that mediates between the host and pathogenic microorganisms. These bacteria colonize the skin surface and actively inhibit MRSA transfer through competitive exclusion and antimicrobial mechanisms, providing superior protection compared to traditional disinfectants

Inventive Principle:
Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent changes the biological parameter of the skin surface by introducing probiotic bacteria that alter the microbial ecosystem. This transforms the skin from a passive surface to an active defensive barrier, reducing pathogen transfer by up to 99% through microbial community modulation

Inventive Principle:
Principle #35Parameter changes

2Reliability

If antibiotic treatment is used to treat MRSA infections, then infection is treated, but antibiotic resistance develops and treatment options are limited

Engineering Contradiction:
Improveinfection treatment effectivenessVSAvoidantibiotic resistance
Core Design Contradiction:
ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The patent converts the harmful effect of antibiotic resistance into a benefit by using non-pathogenic lactic acid bacteria that inhibit MRSA through non-antibiotic mechanisms. This approach eliminates the selective pressure for resistance while maintaining effective infection control

Inventive Principle:
Principle #22Blessing in disguise (Convert harm into benefit)

Solution Approach 2:

The lactic acid bacteria provide self-service protection by colonizing the skin and maintaining a protective microbial ecosystem. The bacteria continuously inhibit pathogen transfer through their metabolic activities and competitive interactions, eliminating the need for external antibiotic intervention

Inventive Principle:
Principle #25Self-service

3Object-affected harmful factors

If lactic acid bacteria are applied to reduce MRSA transfer, then pathogen transfer is decreased by up to 99%, but the mechanism involves complex microbial interactions

Engineering Contradiction:
Improvepathogen transfer reductionVSAvoidmicrobial interaction mechanism
Core Design Contradiction:
Object-affected harmful factorsVSDevice complexity

Solution Approach 1:

The patent segments the complex microbial interaction into distinct functional components: lactic acid bacteria colonization, competitive exclusion of MRSA, and antimicrobial substance production. This segmentation simplifies the understanding of how probiotics reduce pathogen transfer through multiple coordinated mechanisms

Inventive Principle:
Principle #1Segmentation

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The use of lactic acid bacteria effectively decreases the transfer of MRSA by up to 99% between subjects and surfaces, providing a non-pathogenic and gut microbiota-safe solution to prevent infections and reduce antibiotic resistance.

Implementation Method 1

The use of lactic acid bacteria effectively decreases the transfer of MRSA by up to 99% between subjects and surfaces

Methodology Applied
Scientific EffectCompetitive exclusion:

Implementation Method 2

Lactobacillus and Enterococcus strains are applied topically or as oral supplements to inhibit the colonization and transfer of MRSA

Methodology Applied
Scientific EffectAntimicrobial activity:

Data Source

PatentUS12150968B2Method for reducing the transfer of pathogenic microorganisms
Publication Date: 2024.11.26 LOREAL SA

AI summary

The present invention relates to a composition comprising at least one lactic acid bacterium for use in decreasing the transfer of a pathogenic microorganism between a surface of a first subject and a surface of a second subject.